公开(公告)号：US20230338525A1

公开(公告)日：2023-10-26

申请号：US18066581

申请日：2022-12-15

申请人： KINGS COLLEGE LONDON ,  THE TRUSTEES OF DARTMOUTH COLLEGE

发明人： Randolph NOELLE

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K39/39 ,  A61K47/68 ,  A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  C12N15/113

CPC分类号： A61K39/39566 ,  A61K39/3955 ,  C07K16/2827 ,  C07K16/2878 ,  A61K39/39 ,  A61K47/6851 ,  A61K35/17 ,  A61K39/0011 ,  A61K45/06 ,  C12N15/113 ,  C12N15/1138 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  A61K2039/5152 ,  A61K2039/55516 ,  Y02A50/30 ,  A61K2039/5256 ,  C12N2310/14 ,  C12N2710/10034 ,  C12N2710/10043

摘要： The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

公开(公告)号：US20190209677A1

公开(公告)日：2019-07-11

申请号：US16334683

申请日：2017-09-21

申请人： The Governors of the University of Alberta

发明人： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC分类号： A61K39/29

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55544 ,  A61K2039/70 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2770/24234

摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US20180344832A1

公开(公告)日：2018-12-06

申请号：US15564413

申请日：2016-04-20

申请人： ETUBICS CORPORATION

发明人： Frank R. JONES ,  Elizabeth GABITZSCH ,  Yvette LATCHMAN ,  Adrian RICE

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K31/519 ,  A61K31/513 ,  A61K31/282 ,  A61K38/17 ,  C12N15/86

CPC分类号： C07K16/3007 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/505 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/572 ,  A61K2039/575 ,  C07K16/081 ,  C07K16/2818 ,  C07K2317/76 ,  C12N2710/10034 ,  C12N2710/10041 ,  C12N2710/20034 ,  Y02A50/464

摘要： Methods and compositions for generating immune responses using adenovirus vectors that allow multiple vaccinations or in combination with other therapy and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US20180078507A1

公开(公告)日：2018-03-22

申请号：US15706335

申请日：2017-09-15

申请人： Auburn University ,  Altimmune, Inc.

发明人： Allan E. David ,  Henry J. Baker ,  Aime K. Johnson ,  M. Scot Roberts ,  Kent R. Van Kampen ,  Prachi Sangle

IPC分类号： A61K9/50 ,  A61K9/19 ,  A61K9/00 ,  A61K39/235 ,  A61K39/145

CPC分类号： A61K9/5036 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/19 ,  A61K9/5031 ,  A61K9/5153 ,  A61K39/12 ,  A61K39/145 ,  A61K39/235 ,  A61K2039/55555 ,  A61P31/16 ,  A61P31/20 ,  C12N2710/10034 ,  C12N2710/10343 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/16134

摘要： Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided. Pharmaceutical formulations providing a single dose composition are also provided, along with methods for administering the pharmaceutical compositions to a subject in need thereof a therapeutically effective amount of an active agent are provided.

公开(公告)号：US09701718B2

公开(公告)日：2017-07-11

申请号：US13994532

申请日：2011-12-14

申请人： Nancy J. Sullivan ,  Gary J. Nabel ,  Clement Asiedu ,  Cheng Cheng ,  Maria Grazia Pau ,  Jaap Goudsmit

发明人： Nancy J. Sullivan ,  Gary J. Nabel ,  Clement Asiedu ,  Cheng Cheng ,  Maria Grazia Pau ,  Jaap Goudsmit

IPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2760/14034 ,  C12N2760/14134

摘要： Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

公开(公告)号：US20170165341A1

公开(公告)日：2017-06-15

申请号：US15433934

申请日：2017-02-15

申请人： Etubics Corporation

发明人： Frank R. Jones ,  Elizabeth Gabitzsch

IPC分类号： A61K39/00 ,  C12N7/00 ,  C12N15/86 ,  C07K14/47

CPC分类号： C12N15/86 ,  A61K39/0011 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/4748 ,  C07K14/70503 ,  C07K14/70596 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2799/022

摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US09605275B2

公开(公告)日：2017-03-28

申请号：US14143104

申请日：2013-12-30

申请人： Altimmune Inc.

发明人： De-Chu C. Tang

IPC分类号： A61K35/761 ,  A61K39/12 ,  C12N15/86 ,  A61K39/00 ,  A61K39/145 ,  A61K39/155 ,  A61K39/07

CPC分类号： C12N15/86 ,  A61K39/00 ,  A61K39/07 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/58 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2760/16134

摘要： The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

公开(公告)号：US09533036B2

公开(公告)日：2017-01-03

申请号：US11593458

申请日：2006-11-06

申请人： Yucheng Tang ,  Albert Deisseroth

发明人： Yucheng Tang ,  Albert Deisseroth

IPC分类号： C07K14/705 ,  A61K39/145 ,  C07K14/005 ,  A61K39/39 ,  A61K39/12 ,  A61K39/00 ,  A61K39/385

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/385 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/005 ,  C07K14/70575 ,  C07K2319/02 ,  C07K2319/06 ,  C07K2319/33 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/20034 ,  C12N2760/16122 ,  C12N2760/16134

摘要： Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.

摘要翻译： 提供了产生对任何各种抗原（包括外来抗原如感染性抗原）的免疫应答的方法。 通常，该方法包括施用编码编码可分泌融合蛋白的转录单位的表达载体，含有外源抗原和CD40配体的融合蛋白，并施用编码的融合蛋白。 在另一种方法中，使用编码的融合蛋白引发对外来抗原的免疫应答，而不施用载体。 本发明的方法可以用于免疫个体免受传染病如流感病毒的感染。 还描述了在老年人中获得免疫应答的方法。

公开(公告)号：US20160250312A1

公开(公告)日：2016-09-01

申请号：US15028547

申请日：2014-10-13

申请人： ISIS INNOVATION LIMITED ,  ACADEMISCH ZIEKENHUIS LEIDEN (ALSO ACTING UNDER THE NAME OF LEIDEN UNIVERSITY MEDICAL)

发明人： Rhea Longley ,  Ahmed Salman ,  Alexandra Spencer ,  Adrian Hill ,  Chris Janse ,  Sahid Khan

IPC分类号： A61K39/015 ,  C12N15/86 ,  C12N7/00 ,  C07K14/445 ,  C07K14/005

CPC分类号： A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K14/445 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10021 ,  C12N2710/10022 ,  C12N2710/10023 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/24021 ,  C12N2710/24022 ,  C12N2710/24023 ,  C12N2710/24034 ,  C12N2710/24043 ,  Y02A50/412

摘要： The invention relates to an antigenic composition or vaccine comprising a viral vector, the viral vector comprising nucleic acid encoding Plasmodium protein PfLSA1, or a part or variant of Plasmodium protein PfLSA1; PfLSAP2, or a part or variant of Plasmodium protein PfLSAP2; PfUIS3, or a part or variant of Plasmodium protein PfUIS3; PfI0580c, or a part or variant of Plasmodium protein PfI0580c; and PfSPECT-1, or a part or variant of Plasmodium protein PfSPECT-1.

摘要翻译： 本发明涉及包含病毒载体的抗原组合物或疫苗，所述病毒载体包含编码疟原虫蛋白PfLSA1的核酸或疟原虫蛋白PfLSA1的部分或变体; PfLSAP2或疟原虫蛋白PfLSAP2的一部分或变体; PfUIS3或疟原虫蛋白PfUIS3的部分或变体; PfI0580c，或疟原虫蛋白PfI0580c的部分或变体; 和PfSPECT-1，或疟原虫蛋白PfSPECT-1的部分或变体。

公开(公告)号：US20130122038A1

公开(公告)日：2013-05-16

申请号：US13675447

申请日：2012-11-13

申请人： Crucell Holland B.V. ,  THE UNITED STATES OF AMERICA AS REPRE

发明人： Katarina RADOSEVIC ,  Mario Roederer ,  Diane Bolton ,  Jerôme H.H.V. Custers

IPC分类号： A61K35/76

CPC分类号： A61K35/761 ,  A61K39/12 ,  A61K39/165 ,  A61K39/21 ,  A61K39/235 ,  A61K2039/5256 ,  A61K2039/541 ,  A61K2039/544 ,  A61K2039/545 ,  A61K2039/58 ,  A61K2039/70 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2740/15034 ,  C12N2760/16234 ,  C12N2760/18034 ,  C12N2760/18434 ,  C12N2760/18443

摘要： The invention provides reagents and methods for heterologous prime-boost immunization regimens. In particular, the invention provides reagents and methods for use in a paramyxovirus-based prime and adenovirus-based boost immunization system, wherein the immunization induces an immune response to a foreign antigen.

摘要翻译： 本发明提供用于异源初免 - 加强免疫方案的试剂和方法。 特别地，本发明提供了用于基于副基因和腺病毒的加强免疫系统中的试剂和方法，其中免疫诱导对外源抗原的免疫应答。